

542049

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number
WO 2004/084862 A1

- (51) International Patent Classification⁷: **A61K 9/16**
- (21) International Application Number:
PCT/EP2004/002821
- (22) International Filing Date: 18 March 2004 (18.03.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
03007009.8 27 March 2003 (27.03.2003) EP
- (71) Applicant (*for all designated States except US*): **DSM IP ASSETS B.V.** [NL/NL]; Het Overloon 1, NL-6411 TE Heerlen (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **DIGUET, Sylvain** [FR/FR]; 28, rue d'Allschwil, F-68220 Neuwiller (FR). **HUBER, Torsten** [DE/CH]; Schildmatt 1, CH-4312 Magden (CH). **ULM, Johann** [CH/CH]; Im Goldbrunnen 32, CH-4104 Oberwil (CH).
- (74) Agent: **SCHWANDER, Kuno, Josef**; Roche Vitamins Ltd., Wurmisweg 576, CH-4303 Kaiseraugst (CH).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: PROCESS FOR THE PRODUCTION OF CROSS-LINKED GELATIN BEADLETS

(57) Abstract: The invention provides a process for the production of cross-linked beadlets containing one or more active ingredients selected from the group of a fat-soluble vitamin active material, a carotenoid and a polyunsaturated fatty acid, the process comprising treating a dry particulate form at a temperature in the range of from 90°C to 140°C for a time period of from 30 seconds to 30 minutes or from 1 minute to 10 minutes or from 3 minutes to 7 minutes.

WO 2004/084862 A1

PROCESS FOR THE PRODUCTION OF CROSS-LINKED GELATIN MICROBEADLETS

FIELD OF THE INVENTION

The present invention relates to a process for the production of beadlets with a high concentration of an active ingredient selected from a fat soluble vitamin, a carotenoid and a polyunsaturated fatty acid, to the resulting beadlets and to compositions containing them.

SUMMARY OF THE INVENTION

More particularly the invention provides a process for the production of cross-linked beadlets containing one or more active ingredients selected from the group of a fat-soluble vitamin active material, a carotenoid and a polyunsaturated fatty acid, the process comprising treating a dry particulate form at a temperature in the range of from 90°C to 140°C for a time period of from 30 seconds to 30 minutes or from 1 minute to 10 minutes or from 3 minutes to 7 minutes.

DETAILED DESCRIPTION

Examples of a fat-soluble vitamin active material include vitamin bearing oils, provitamins and pure or substantially pure vitamins, both natural and synthetic, or chemical derivatives thereof and mixtures thereof. Of particular interest is a vitamin selected from the group of vitamins A, D, E and K, and derivatives thereof. For example, the term "Vitamin E" includes synthetically manufactured tocopherols or a mixture of natural tocopherols. Examples of vitamin derivatives include vitamin A acetate, vitamin A palmitate and vitamin E acetate. An example for a vitamin D-active material is vitamin D₃. As a particular example, the process of the present invention may result in a beadlet containing a vitamin A-active material and a vitamin D-active material, e.g. vitamin A and vitamin D₃.

In one embodiment the process of the invention may involve Vitamin A as fat-soluble vitamin active material in a total concentration in the range of from 500,000 IU vitamin A/g beadlet to 1,500,000 IU vitamin A/g beadlet, in the range of from 750,000 IU vitamin A/g beadlet to 1,500,000 IU vitamin A/g beadlet, or in the range of from 750,000 IU vitamin A/g beadlet to 1,300,000 IU vitamin A/g beadlet, e.g. vitamin A may be present in the beadlet in a total concentration of 500,000 \pm 35,000 IU active ingredient/g beadlet, 750,000 \pm 35,000 IU active ingredient/g beadlet, of 1,000,000 \pm 35,000 IU active ingredient/g beadlet, or of 1,100,000 \pm 35,000 IU active ingredient/g beadlet. Vitamin D as fat-soluble vitamin active material may be present in the range of from 100,000 IU vitamin D/g beadlet to 500,000 IU vitamin D/g beadlet or in the range of from 100,000 IU vitamin D/g beadlet to 200,000 IU vitamin D/g beadlet, vitamin E as fat-soluble vitamin active material may be present in the range of from 50 % to 75 % vitamin E.

Examples for a carotenoid include β -carotene, lycopene, zeaxanthin, astaxanthin, lutein, capsanthin and cryptoxanthin.

In one embodiment the process of the invention may involve a carotenoid in a total concentration in the range of from 5 % to 20 %, in the range of from 5 % to 15 %, or in the range of from 7 % to 15 %.

Examples for a polyunsaturated fatty acid, as triglyceride and/or ethylester, include arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid and γ -linolenic acid and/or ethylester.

In one embodiment the process of the invention may involve a polyunsaturated fatty acid as triglyceride in a total concentration in the range of from 20 % to 50 %, in the range of from 25 % to 40 %, or in the range of from 28 % to 38 %.

The dry particulate forms used in the process of the present invention may be prepared by any procedure known to the skilled artisan, e.g. by forming an aqueous emulsion containing the active ingredient, an emulsifier, a texturing agent and a reducing sugar, followed by converting the emulsion to a dry particulate form containing the non-aqueous constituents of said emulsion.

Examples for an emulsifier are gelatine and ascorbyl palmitate. Gelatine is an emulsifier which at the same time functions as a texturing agent. Any gelatine which has a "bloom" in the range of practically zero to about 300 can be employed in the practice of the present invention. Both Type A and Type B gelatine can be employed. The preferred gelatine used

is Bloom 140, but gelatine Bloom 30 or Bloom 75 would be possible as well. In the presence of gelatine no additional texturing agent may be necessary.

The concentration of the emulsifier depends on the kind of emulsifier used, e.g. gelatine may be present in a concentration in the range of from 25 % to 35 %, or less.

- 5 Examples for a texturing agent beyond gelatine include carrageenan, modified starch, modified cellulose, xanthan gum, acacia gum, pectins, guar, caroub gums, maltodextrines and alginates.

The concentration of the texturing agent depends on the kind of texturing agent used and may be, e.g., in the range of from 0 % to 15 %.

- 10 Examples for a reducing sugar are fructose, glucose, lactose, maltose, xylose, arabinose, ribose and sucrose. One type of sugar may be used or a mixture of two or more sugars. The reducing sugar may be added as such or in the form of a syrup, e.g. fructose or glucose syrup.

- The concentration of the reducing sugar depends on the kind of reducing sugar used and may be, e.g., in the range of from 2 % to 10 %, or in a ratio of gelatine:sugar in the range of from 3:1 to 7:1, e.g. 5:1.

- Small quantities of other ingredients may be incorporated including antioxidants like 6-ethoxy-1,2-dihydroxy-2,2,4-trimethylquinoline (ethoxyquine), 3,5-di-tertiary-4-butyl hydroxytoluene (BHT) and 3-tertiary butyl-hydroxyanisole (BHA), humectants such as glycerol, sorbitol, polyethylene glycol, propylene glycol, extenders and solubilizers.

- As a typical example gelatine and a suitable sugar may be dissolved in water previously mixed with glycerin. The dissolution may last at 65-70°C for, e.g., about 30 minutes. Then, e.g., the vitamin A with the antioxidant may be added and emulsified. The pre-emulsification may be done with a colloid mill, e.g., based on a rotor/stator principle. The pre-emulsification may be hold for between 15 and 30 minutes at a rotation speed of the rotor between 500 and 1500 rpm and may then pass through a high pressure homogeniser resulting in a conversion of the emulsion to fine droplets.

- In one example the conversion of emulsion droplets to "set up" particles may be attained by introducing a spray of emulsion droplets into an agitated cloud or suspension in air of the particles of the finely dispersed powder, e.g. by forcing the emulsion through a revolving spray head into a suspension in air of the powdered material, contained in and agitated by a revolving cylindrical drum, the drum and the spray head rotating in opposite

directions so that the cloud or suspension of the powder in air is swirling in a sense of rotation opposite to the entering emulsion spray.

Examples of the finely dispersed powder used in the process to collect/coat the droplets of the emulsion include polysaccharides such as starch and modified starch, and calcium

- 5 silicate alone or a mixture of calcium silicate with one of the following mixture components: microcrystalline cellulose, magnesium silicate, magnesium oxide, stearic acid, calcium stearate, magnesium stearate, hydrophilic silicic acid and kaolin. Coatings which consist of calcium silicate alone are preferred. The calcium silicate may be present wholly or partially in the form of the hydrate.
- 10 The calcium silicate particles are especially suitable when they have a size of less than 0.2 μm , especially less than 0.1 μm , and a specific surface of at least about 80 m^2/g to about 180 m^2/g , preferably of about 95 m^2/g to 120 m^2/g , and are agglomerated to aggregates having an average size of about 5-30 μm , preferably 5-20 μm . The SiO_2/CaO ratio lies between 1.65 and 2.65.
- 15 In coatings which consist of calcium silicate alone, the amount of calcium silicate may be in the range of from 2 wt.% to 12 wt.%, preferably in the range of from 4 wt.% to 9 wt.%.
In coatings consisting of a mixture of calcium silicate with one or more of the aforementioned mixture components, the amount of the calcium silicate mixture may be in the range of from 5 wt.% to 25 wt.%.
- 20 Optionally, the resulting dry particulate forms may be separated from the remaining finely dispersed powder. This may be accomplished by operations which are conventional per se, including, e.g. simply to feed the mixture of powder and dry particulate forms to a shaking screen of a size selected to retain the dry particulate forms while passing the collecting powder.
- 25 For further processing those dry particulate forms containing the active material are preferred having a moisture content of less than 10 % and preferably between about 4 to 6 percent. If the moisture content is higher the dry particulate forms may be dried to the desired moisture content by various methods, e.g. by exposing them to air at room temperature or by moderate heating in a drying oven at 37°C to 45°C.
- 30 The heat treatment may, e.g., be achieved in a batch or in a continuous process where the beadlet residence time and temperature are controlled.

In the case of a fluid bed process, the beadlet is added either at the beginning in the case of the batch process or constantly in the case of a continuous fluid bed in a hot air or nitrogen stream having a temperature between 100 and 200°C, preferably between 130-160°C. The beadlet temperature is raised in a few second to one minute above 100°C
5 enabling a quick and efficient reaction. The beadlet is ready after 5 to 10 minutes. The beadlet is cooled at the end of the treatment.

In the case of a continuous flash treatment, the beadlet is fed continuously into a hot gas stream having a temperature between 100 and 200°C, preferably between 130-160°C. The beadlet can be moved by mechanical stirring, e.g., above 300 rpm. The wall of the vessel
10 used to make this thermal treatment can also be heated to a temperature in the range of from 110 to 180°C. The desired crosslinking of the beadlet may be reached in a time in the range of from 30 seconds to 10 minutes or from 1 minute to 10 minutes, with a maximum beadlet temperature in the range of from 90°C to 140°C, preferably from 105°C to 125°C.

The beadlet forms resulting from the inventive process have a core and a surface region,
15 wherein the loss of active ingredients in the surface region is reduced, and are also an object of the present invention.

Therefore, the present invention further provides a beadlet form having a core and a surface region, wherein the core region contains, in a high concentration, one or more active ingredients selected from the group of a fat-soluble vitamin active material, a
20 carotenoid and a polyunsaturated fatty acid, and the surface region contains less than 10 % of the total active ingredient content, preferably less than 5 % of the total active ingredient content.

In one embodiment the present invention provides a beadlet form containing one or more active ingredients selected from the group of Vitamin A in a total concentration in the
25 range of from 800,000 IU vitamin A/g beadlet to 1,500,000 IU vitamin A/g beadlet or in the range of from 950,000 IU vitamin A/g beadlet to 1,250,000 IU vitamin A/g beadlet, in a total concentration in the range of from 100,000 IU vitamin D/g beadlet to 500,000 IU vitamin D/g beadlet or in the range of from 100,000 IU vitamin D/g beadlet to 200,000 IU vitamin D/g beadlet, vitamin E in a total concentration in the range of from 50 % to 75 %, a carotenoid in a total concentration in the range of from 5 to 20% and a polyunsaturated
30 fatty acid in a total concentration in the range of from 5 to 50%, wherein the surface region contains less than 10 % of the total active ingredient content. In another embodiment the surface region contains less than 5 % of the total active ingredient content.

The beadlets are characterized by high stability and potency. They exhibit high stability when pelletized, e.g. they withstand the temperature, moisture and pressure of a feed pelleting process without losing their physical integrity. They are water insoluble and maintain their properties in relation to bioavailability.

- 5 Typical examples of beadlets of the present invention may, e.g. have the following components: 30 % to 45 % of vitamin A, 0 % to 2 % of vitamin D₃, 5 % to 15 % of 6-ethoxy-1,2-dihydro-2,2,4-trimethylquinoline (EMQ), 25 % to 35 % of gelatine, 5 % to 10 % of fructose, 2 % to 10 % of glycerine, 5 % to 10 % of calcium silicate, 0 % to 25 % of corn starch, 0 % to 1 % of edible fat, and water.
- 10 **Example 1: Preparation of beadlets containing 1,000,000 IU vitamin A/g beadlet plus 200,000 IU vitamin D₃/g beadlet**

Approximately 90 parts of gelatine Bloom 140 and 18 parts of fructose were dissolved in 313.2 parts of water (containing 23.2 parts of glycerin) by heating at 65°C. 158 parts of Vitamin A containing 24% ethoxyquin (assay 2.1 Mio. IU vitamin A per g) and 3.5 parts of
 15 vitamin D₃ (assay 20 Mio. IU vitamin D₃ per g) were then mixed with the resulting matrix, followed by pre-emulsification.

The beadlet was sprayed using as finely dispersed powder calcium silicate. The average particle size of the beadlet was in the range of from 200 µm to 300 µm.

20 The beadlet was divided into two groups: one group was treated using a classical heated slow mixer without sufficient control of the thermal history of the beadlet, and the other group was treated by a fluidized bed, i.e. a batch process with an apparatus where the temperature and residence time of the beadlet can be controlled. The results are compared in the following table:

	heated slow mixer	fluidized bed
Vitamin A content after crosslinking (IU/g)	1,025,000	1,050,000
Vitamin A Loss (%)	3-4	0-1
Surface vitamin A (%)	8-10	1-2
Crosslinking grade (%)	76%	82%

- 25 In the fluidized bed the temperature was controlled between 100 and 115°C for 5 minutes. In the heated slow mixer, the beadlet was heated for about 15 minutes at a temperature raising from 90°C to 124°C.

Example 2: Preparation of beadlets containing 1,000,000 IU vitamin A/g beadlet

Approximately 100 parts of gelatine Bloom 140 and 20 parts of fructose were dissolved in 308.2 parts of water (containing 13.2 parts of glycerin) by heating at 65°C. 170 parts of Vitamin A containing 24% ethoxyquin (assay 2.1 Mio. IU vitamin A per g) were then
5 mixed with the resulting matrix, followed by pre-emulsification.

The beadlet was sprayed using as finely dispersed powder calcium silicate. The average particle size of the beadlet was in the range of from 180 µm to 270 µm.

The beadlet was divided into three groups: the first group was treated using a classical heated slow mixer as in Example 1, the second group was treated by a fluidized bed as in
10 Example 1, the third group was treated by a continuous flash treatment in diluted phase wherein the flash treatment is ensured by a combination of pneumatic transport and mechanical transport.. The results are compared in the following table:

	heated slow mixer	fluidized bed	flash treatment
Vitamin A content after crosslinking (IU/g)	1,119,000	1,146,000	1,143,000
Vitamin A Loss (%)	3-4	0-1	0-1
Surface vitamin A (%)	8-10	2-2.5	3-5
Crosslinking grade (%)	50-80	50-80	50-80

In the fluidized bed the temperature was controlled between 110 and 120°C for 5 minutes.
15 In the flash treatment, the beadlet was treated for 1 to 4 minutes at a temperature raising from 115°C to 125°C. In the heated slow mixer, the beadlet was heated for about 20 minutes at a temperature raising from 70°C to 124°C.

Example 3: Stability of beadlets containing a high concentration of Vitamin A

Typical stability performance in terms of retention time after a storage time of 4 weeks at
20 40°C and 75 % rH for the cross-linked beadlets of Example 1 and Example 2 are about 90-95 % which is comparable to standard cross-linked vitamin A forms containing 500'00 IU vitamin A/g active ingredient.

Example 4: Preparation of beadlets containing 1,000,000 IU vitamin A/g beadlet

Approximately 100 parts of gelatine Bloom 140 and 20 parts of fructose were dissolved in
25 308.2 parts of water (containing 13.2 parts of glycerin) by heating at 65°C. 170 parts of

Vitamin A containing 24% ethoxyquin (assay 2.1 Mio. IU vitamin A per g) were then mixed with the resulting matrix, followed by pre-emulsification.

The beadlet was sprayed using as finely dispersed powder calcium silicate. The average particle size of the beadlet was in the range of from 200µm to 300µm.

- 5 The beadlets of 3 lots were treated by a continuous flash treatment in diluted phase wherein the flash treatment is ensured by a combination of pneumatic transport and mechanical transport. The results are compared in the following table:

	Lot 1	Lot 2	Lot 3
Vitamin A content after crosslinking (IU/g)	1'064'808	1'051'641	1'077'224
Vitamin A Loss (%)	<1	<1	<1
Surface vitamin A (%)	3.7	4.0	3.5
Crosslinking grade (%)	60-85	60-85	60-85

- 10 In the flash treatment, the beadlet was treated for 1 to 5 minutes at a temperature raising from 105°C to 115°C.

Example 5: Stability of beadlets containing a high concentration of Vitamin A

- Typical stability performances in terms of retention time after a storage time of 4 weeks at 40°C and 75 % rH for the cross-linked beadlets of Example 4 are about 95-100 % which are comparable to standard cross-linked vitamin A forms containing 500'00 IU vitamin
15 A/g active ingredient.

Example 6: Preparation of beadlets containing 1,000,000 IU vitamin A/g beadlet plus 200,000 IU vitamin D₃/g beadlet

- Approximately 90 parts of gelatine Bloom 140 and 18 parts of fructose were dissolved in 313.2 parts of water (containing 23.2 parts of glycerin) by heating at 65°C. 158 parts of
20 Vitamin A containing 24% ethoxyquin (assay 2.1 Mio. IU vitamin A per g) and 3.5 parts of vitamin D₃ (assay 20 Mio. IU vitamin D₃ per g) were then mixed with the resulting matrix, followed by pre-emulsification.

The beadlet was sprayed using as finely dispersed powder calcium silicate. The average particle size of the beadlet was in the range of from 200µm to 300µm.

The beadlets of 3 lots were treated by a continuous flash treatment in diluted phase wherein the flash treatment is ensured by a combination of pneumatic transport and mechanical transport. The results are compared in the following table:

	Lot 1	Lot 2	Lot 3
Vitamin A content after crosslinking (IU/g)	1'105'039	1'074'633	1'077'470
Vitamin D3 content after crosslinking (IU/g)	218'617	214'813	217'858
Vitamin A Loss (%)	<1	<1	<1
Surface vitamin A (%)	4.7	4.7	4.6
Crosslinking grade (%)	60-85	60-85	60-85

- 5 In the flash treatment, the beadlet was treated for 1 to 5 minutes at a temperature raising from 105°C to 115°C.

Example 7: Stability of beadlets containing a high concentration of Vitamin A and D3

- Typical stability performances in terms of retention time after a storage time of 4 weeks at 40°C and 75 % rH for the cross-linked beadlets of Example 6 are about 95-100 % and
- 10 about 100% for vitamin A and D3 respectively, which are comparable to standard cross-linked vitamin AD3 forms containing 500'00 IU vitamin A/g and 100'000 IU vitamin D3/g active ingredient.

CLAIMS

1. A process for the production of cross-linked beadlets containing one or more active ingredients selected from the group of a fat-soluble vitamin active material, a carotenoid and a polyunsaturated fatty acid,
- 5 the process comprising treating a dry particulate form at a temperature in the range of from 90°C to 140°C for a time period of from 30 seconds to 30 minutes or from 1 minute to 10 minutes or from 3 minutes to 7 minutes.
2. The process according to claim 1 wherein the fat-soluble vitamin active material is
- 10 selected from vitamin A, vitamin D and vitamin E, the carotenoid is selected from β -carotene, lycopene, zeaxanthin, astaxanthin, lutein, capsanthin and cryptoxanthin and the polyunsaturated fatty acid is selected from arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid and γ -linolenic acid and triglycerides and ethylesters thereof.
3. The process according to claim 2 wherein the concentration of the fat-soluble vitamin
- 15 active material, the carotenoid and the polyunsaturated fatty acid is selected from a total concentration in the range of from 500,000 IU vitamin A/g beadlet to 1,500,000 IU vitamin A/g beadlet, in the range of from 100,000 IU vitamin D/g beadlet to 500,000 IU vitamin D/g beadlet, in the range of from 50 % to 75 % vitamin E, in the range of from 5 % to 20 % of carotenoid and in the range of from 20 % to 50 % polyunsaturated fatty acid
- 20 as triglyceride.
4. The process according to claim 1 wherein the dry particulate forms have a moisture content of less than 10 %.
5. The process according to claim 1 wherein the heat treatment is achieved in a batch or in a continuous process where the beadlet residence time and temperature are controlled.
- 25 6. The process according to claim 1 wherein the beadlet is added in a hot air or nitrogen stream having a temperature between 100 and 200°C.
7. The process according to claim 1 wherein after addition of the dry particulate form the temperature is raised in a time in the range of from a few seconds to 1 minute above 100°C.
- 30 8. The process according to claim 1 wherein heating takes place at a maximum beadlet temperature in the range of from 110°C to 140°C.

9. A cross-linked beadlet form having a core and a surface region, wherein the core region contains, in a high concentration, one or more active ingredients selected from the group of a fat-soluble vitamin active material, a carotenoid and a polyunsaturated fatty acid, and the surface region contains less than 10 % or less than 5 % of the total active ingredient content.
10. A cross-linked beadlet form containing one or more active ingredients selected from the group of Vitamin A in a total concentration in the range of from 800,000 IU vitamin A/g beadlet to 1,500,000 IU vitamin A/g beadlet, in a total concentration in the range of from 100,000 IU vitamin D/g beadlet to 500,000 IU vitamin D/g beadlet, vitamin E in a total concentration in the range of from 50 % to 75 %, a carotenoid in a total concentration in the range of from 5 to 20% and a polyunsaturated fatty acid in a total concentration in the range of from 5 to 50%, wherein the surface region contains less than 10 % or less than 5 % of the total active ingredient content.
11. The cross-linked beadlet form according to claim 10 having the following components:
- 30 % to 45 % of vitamin A, 0 % to 2 % of vitamin D₃, 5 % to 15 % of 6-ethoxy-1,2-dihydro-2,2,4-trimethylquinoline, 25 % to 35 % of gelatine, 5 % to 10 % of fructose, 2 % to 10 % of glycerine, 5 % to 10 % of calcium silicate, 0 % to 25 % of corn starch, 0 % to 1 % of edible fat, and water.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/002821

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 670 247 A (SCIALPI LEONARD J) 2 June 1987 (1987-06-02) the whole document	1-11
X	GB 993 138 A (PFIZER & CO C) 26 May 1965 (1965-05-26) the whole document	1-11
X	EP 0 285 682 A (HOFFMANN LA ROCHE) 12 October 1988 (1988-10-12) the whole document	1-11
X	US 5 126 328 A (CHAUNDY FREDERICK K ET AL) 30 June 1992 (1992-06-30) the whole document	1-11
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

18 August 2004

Date of mailing of the international search report

26/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Giménez Miralles, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/002821

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X.	WO 03/017785 A (LEUENBERGER BRUNO ; ROCHE VITAMINS AG (CH)) 6 March 2003 (2003-03-06) the whole document	1-11
X	US 5 356 636 A (SCHNEIDER JOACHIM U ET AL) 18 October 1994 (1994-10-18) the whole document	1-11
X	EP 1 074 592 A (HOFFMANN LA ROCHE) 7 February 2001 (2001-02-07) the whole document	1-11
Y	WO 91/17821 A (DANOCHEMO AS) 28 November 1991 (1991-11-28) examples	1-11
Y	FR 2 243 727 A (STORK AMSTERDAM) 11 April 1975 (1975-04-11) the whole document	1-11
Y	US 5 487 916 A (CHRISTENSEN BORGE H) 30 January 1996 (1996-01-30) the whole document	1-11
Y	US 5 364 563 A (STOLLER HANSJOERG ET AL) 15 November 1994 (1994-11-15) examples	1-11
Y	EP 0 982 038 A (BASF AG) 1 March 2000 (2000-03-01) example 1	1-11
Y	US 5 811 609 A (JENSEN NINA MUSAEUS ET AL) 22 September 1998 (1998-09-22) examples	1-11
Y	EP 0 807 431 A (HOFFMANN LA ROCHE) 19 November 1997 (1997-11-19) the whole document	1-11
Y	US 5 668 183 A (LEUENBERGER BRUNO) 16 September 1997 (1997-09-16) the whole document	1-11
A	CORTESI R ET AL: "Sugar cross-linked gelatin for controlled release: microspheres and disks" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 19, no. 18, September 1998 (1998-09), pages 1641-1649, XP004161435 ISSN: 0142-9612	1-11

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/002821

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-11 partly
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Claims Nos.: 1-11 partly

Present independent claims 1, 9 and 10 relate to an extremely large number of possible cross-linked microbeadlets, because the composition of the material forming the microbeadlets' matrix is not defined in the claims or is defined in an extremely vague way ("dry particulate form"). In fact, the claims cover so many possibilities that a lack of clarity (and conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible.

Further, the claims lack support in the description over their whole extent, or the application lacks disclosure. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found only for "dry particulate forms" consisting of spray-dried microbeadlets comprising a matrix core of gelatin and a reducing sugar (fructose) and a coating of an inorganic material (calcium silicate). Since the features relating to the cross-linking of the matrix depend on the matrix' nature, the nature of the matrix is an essential technical feature of the invention which should be defined in the claims. Generalisation to any "dry particulate form" of any nature is not justified by the extent of the disclosure. Therefore, a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the microbeadlets comprising a matrix core of gelatin and a reducing sugar (fructose) and a coating of an inorganic material (calcium silicate) as disclosed in the description (p.3, 1.21 to p.4, 1.9) and the examples.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/002821

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4670247	A	02-06-1987	EP 0285682 A1 CN 87103281 A ,B JP 2546838 B2 JP 63258807 A AT 64527 T DE 3770940 D1	12-10-1988 16-11-1988 23-10-1996 26-10-1988 15-07-1991 25-07-1991
GB 993138	A	26-05-1965	NONE	
EP 0285682	A	12-10-1988	EP 0285682 A1 AT 64527 T DE 3770940 D1 US 4670247 A	12-10-1988 15-07-1991 25-07-1991 02-06-1987
US 5126328	A	30-06-1992	BR 9200039 A CA 2059104 A1 DE 69118861 D1 DE 69118861 T2 DK 494417 T3 EP 0494417 A2 JP 3210049 B2 JP 5032941 A	08-09-1992 11-07-1992 23-05-1996 05-09-1996 13-05-1996 15-07-1992 17-09-2001 09-02-1993
WO 03017785	A	06-03-2003	BR 0209960 A CA 2450931 A1 WO 03017785 A1 EP 1418822 A1	06-04-2004 06-03-2003 06-03-2003 19-05-2004
US 5356636	A	18-10-1994	DE 4141351 A1 CA 2083754 A1 DE 59205688 D1 DK 547422 T3 EP 0547422 A2 IL 103866 A JP 2519008 B2 JP 6065062 A	17-06-1993 15-06-1993 18-04-1996 01-04-1996 23-06-1993 05-12-1996 31-07-1996 08-03-1994
EP 1074592	A	07-02-2001	EP 1074592 A1 AU 773280 B2 AU 4896300 A BR 0003377 A CA 2314848 A1 CN 1283454 A ID 26741 A JP 2001131060 A NO 20003948 A US 6444227 B1	07-02-2001 20-05-2004 15-02-2001 04-12-2001 05-02-2001 14-02-2001 08-02-2001 15-05-2001 06-02-2001 03-09-2002
WO 9117821	A	28-11-1991	AU 7903191 A WO 9117821 A1 DK 530277 T3 EP 0530277 A1 FI 925101 A	10-12-1991 28-11-1991 02-01-1995 10-03-1993 10-11-1992
FR 2243727	A	11-04-1975	FR 2243727 A1	11-04-1975
US 5487916	A	30-01-1996	AT 155699 T AU 3157393 A	15-08-1997 19-07-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/002821

Patent document
 cited in search report

Publication
 date

Patent family
 member(s)

Publication
 date

US 5487916	A		CA	2125980 A1	24-06-1993
			DE	69221166 D1	04-09-1997
			DE	69221166 T2	05-03-1998
			WO	9311844 A1	24-06-1993
			DK	641236 T3	02-03-1998
			EP	0641236 A1	08-03-1995
			ES	2107001 T3	16-11-1997
			NZ	246148 A	26-01-1996
			RU	2102100 C1	20-01-1998
			AT	153857 T	15-06-1997
			AU	3449193 A	03-08-1993
			DE	69311306 D1	10-07-1997
			DE	69311306 T2	29-01-1998
			WO	9313783 A1	22-07-1993
			DK	621784 T3	22-12-1997
			EP	0621784 A1	02-11-1994
			ES	2105219 T3	16-10-1997
			NZ	246866 A	26-07-1995
			RU	2122406 C1	27-11-1998
			US	5662922 A	02-09-1997
US 5364563	A	15-11-1994	AT	96312 T	15-11-1993
			DE	59003205 D1	02-12-1993
			DK	410236 T3	13-12-1993
			EP	0410236 A2	30-01-1991
			JP	2572877 B2	16-01-1997
			JP	3066615 A	22-03-1991
EP 0982038	A	01-03-2000	DE	19838189 A1	02-03-2000
			AT	230612 T	15-01-2003
			CN	1250650 A	19-04-2000
			DE	59903959 D1	13-02-2003
			EP	0982038 A1	01-03-2000
US 5811609	A	22-09-1998	AT	152754 T	15-05-1997
			AU	6138794 A	14-09-1994
			CA	2156515 A1	01-09-1994
			DE	69403069 D1	12-06-1997
			DE	69403069 T2	06-11-1997
			WO	9419411 A1	01-09-1994
			DK	684973 T3	15-09-1997
			EP	0684973 A1	06-12-1995
			ES	2101512 T3	01-07-1997
EP 0807431	A	19-11-1997	AT	262316 T	15-04-2004
			BR	9703134 A	18-08-1998
			CN	1176760 A , B	25-03-1998
			DE	69728206 D1	29-04-2004
			DK	807431 T3	26-07-2004
			EP	0807431 A2	19-11-1997
			IN	183685 A1	18-03-2000
			JP	10046041 A	17-02-1998
			US	6093348 A	25-07-2000
US 5668183	A	16-09-1997	AT	154822 T	15-07-1997
			DE	59306812 D1	31-07-1997
			DK	565989 T3	15-12-1997
			EP	0565989 A1	20-10-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/002821

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5668183	A	ES 2104990 T3	16-10-1997
		JP 3268883 B2	25-03-2002
		JP 6086642 A	29-03-1994
<hr/>			